SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-046620
Filing Date
2024-05-24
Accepted
2024-05-24 16:01:39
Documents
13
Period of Report
2024-05-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0206714-8k_elevai.htm   iXBRL 8-K 29774
  Complete submission text file 0001213900-24-046620.txt   206064

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE elab-20240521.xsd EX-101.SCH 3033
3 XBRL LABEL FILE elab-20240521_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE elab-20240521_pre.xml EX-101.PRE 22371
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0206714-8k_elevai_htm.xml XML 3795
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 24984126
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)